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The involvement of sympathoadrenal axis activity in obesity onset was investigated using the experimental model of treating
neonatal rats with monosodium L-glutamate. To access general sympathetic nervous system activity, we recorded the ﬁring rates
of sympathetic superior cervical ganglion nerves in animals. Catecholamine content and secretion from isolated adrenal medulla
were measured. Intravenous glucose tolerance test was performed, and isolated pancreatic islets were stimulated with glucose and
adrenergic agonists. The nerve ﬁring rate of obese rats was decreased compared to the rate for lean rats. Basal catecholamine
secretion decreased whereas catecholamine secretion induced by carbachol, elevated extracellular potassium, and caﬀeine in the
isolated adrenal medulla were all increased in obese rats compared to control. Both glucose intolerance and hyperinsulinaemia
were observed in obese rats. Adrenaline strongly inhibited glucose-induced insulin secretion in obese animals. These ﬁndings
suggest that low sympathoadrenal activity contributes to impaired glycaemic control in prediabetic obese rats.
1.Introduction
Obesity is a worldwide epidemic and the most important
factor in metabolic syndrome onset. This syndrome is
part of a group of comorbid pathologies that include in-
sulin resistance, type 2 diabetes, and hypertension [1, 2].
According to the literature, the incidence of these diseases
could double by the year 2030 [3].
Over the past decade, the central nervous system (CNS)
has been recognised as a key player in controlling energy
homeostasis [4]. Although other brain areas are important,
the hypothalamus has been identiﬁed as the pivotal structure
regulating food intake and energy balance [5]. The arcuate
hypothalamic nucleus (ARC) senses peripheral nutrient and
hormonal signals, including insulin and leptin, which are
well-known adiposity signals [6, 7]. The ARC integrates
these peripheral signals, and this information is relayed to
several second-order hypothalamic targets that modulate the
autonomic nervous system (ANS) [8, 9].
The ANS plays a key role in homeostatic control, includ-
ing regulating heart rate, body temperature, blood pressure,
andrespiration[10].TheANSisprimarilyaneﬀerentsystem
that transmits impulses from the hypothalamus to regulate
peripheralorgansystems.TheANSisfurthersubdividedinto
two principal components, the parasympathetic (PNS) and
sympathetic (SNS) nervous systems. In general, activation of
thesplanchnicnerveintheSNSmediatescatabolicprocesses,
whereas stimulation of the vagus nerve in the PNS mediates
anabolic responses [11]. According to Teﬀ, the central
control of insulin secretion is a well-known example of these
opposing processes, as vagal activation enhances insulin
release from pancreatic beta cells, whereas noradrenaline2 Experimental Diabetes Research
released from the SNS inhibits this process [11]. Several
studies have demonstrated a relationship between the SNS
and obesity [10, 12, 13]. Low SNS activity has been proposed
as a risk factor for future body weight gain, as classically
demonstrated by reports from Bray and collaborators that
werebasedonexperimentalevidenceinrodentsshowingthat
lesions in the hypothalamus lead to low SNS activity and
morbid obesity [14, 15].
The sympathoadrenal system includes the SNS and the
chromaﬃn cells from the adrenal medulla, which secretes
catecholamines (primarily adrenaline) into the bloodstream
[16]. Chromaﬃn cells are cholinergically innervated by
the splanchnic nerve from the SNS; acetylcholine released
upon stimulation of this nerve activates neuronal cholinergic
receptors in chromaﬃn cells, thereby inducing membrane
depolarisation and triggering catecholamine secretion [17].
Once secreted, the catecholamines bind to cell-surface
α-a n dβ-adrenergic receptors. In general, activation of
β-adrenergic receptors induces lipolysis, bronchodilation,
vasodilation, thermogenesis, and increased cardiac output;
on the other hand, activating α-adrenergic receptors induces
vasoconstriction and inhibits insulin secretion [18]. High
insulin concentrations in fasting and fed states trigger
insulin resistance. Increased insulin secretion leads to altered
receptorfunctionorpostreceptordefectsininsulinsignalling
[19]. Therefore, pharmacotherapeutic approaches that target
insulin secretion and/or augment sympathetic output have
been pursued in an attempt to either promote weight loss or
attenuate weight gain [20]. The purpose of the present study
was to investigate sympathoadrenal function and its eﬀect in
regulating insulin secretion in pre-diabetic obese rats.
2.MaterialandMethods
2.1. Animals. All animal protocols were performed in accor-
dance with the precepts of the Brazilian College of Animal
Experimentation (COBEA) and Brazilian Federal Law. Once
a day during the ﬁrst 5 days after birth, monosodium L-
glutamate (MSG, 4mg/g body weight) was injected subcu-
taneously into the cervical area of Wistar rat pups. Control
animals received saline solution. The pups were weaned at
21 days of age, and only males were used in the study.
Throughout the protocol period, the animals received water
and commercial chow (Nuvital, Curitiba, Brazil) ad libitum
(except when animals were fasted) and were placed in an
environmentally controlled room maintained at 23 ± 3◦C
with a 12-hour light/12-hour dark photocycle (with the
lights on from 07:00 to 19:00h.).
2.2. Obesity. To evaluate the onset of obesity, 90-day-old
rats were anaesthetised by a lethal intraperitoneal injection
of sodium pentobarbital (45mg/100g body weight). The
epididymal and retroperitoneal fat pads were removed,
rinsed, and weighed to estimate obesity induced by MSG
treatment [21]. The Lee index was calculated using the
formula [(body weight)1/3/(nasoanal length)] × 1000 (where
body weight and length are in g and cm, resp.) and used as a
predictor of obesity in MSG rodents [22].
2.3. Electrical Sympathetic Activity. A f t e rf a s t i n gf o r1 2h r s ,
8 rats from each experimental group were anesthetised
with thiopental (45mg/kg). Following the method of Leon-
Quinto et al., the sympathetic branch nerve from the
superior ganglion was dissected and placed on a pair of
hook-shaped silver recording electrodes (0.6mm diameter)
[23]. The nerve was covered with silicone oil to prevent
dehydration. The electrode was connected to an electronic
device (Bio-Ampliﬁcator, Insight, Riber˜ ao Preto, Brazil) that
ampliﬁed the electrical signal up to 10,000 times after
ﬁltering out low and high frequencies with a 1–80kHz band-
pass ﬁlter. The neural output signal was acquired with an
Insight interface (Insight), viewed online, and stored on a
personal computer using a software program from Insight.
Duringdataacquisition,theanimalswereplacedinaFaraday
cage to block external electromagnetic interference. After
stabilisation, 40 recording frames were analysed from the
signal (over 5–10 minutes) for spike counting. Nerve activity
was quantiﬁed as the number of spikes counted during 5
seconds. For each rat, the average number of spikes per 5
seconds counting trial was used to calculate nerve ﬁring rate.
2.4. Adrenal Glands. Both adrenal glands were removed and
weighed. During handling, the glands were kept on an ice
bath in standard Krebs-HEPES solution containing (in mM)
Cl−, 154.2; Na+, 144.0; Ca2+,2 . 5 ;M g 2+, 1.18; SO4
2−,1 . 2 ;
K+, 3.5; glucose, 11.1; HEPES, 25.0; bovine serum albumin
(BSA) 0.5%. The right glands from both experimental
groups (n = 15 for each group) were used to measure the
total catecholamine (adrenaline and noradrenaline) content
using the trihydroxyindole ﬂuorescence method [24]. The
parameters used were 420nm for excitation and 510nm
for emission. For total catecholamine content, the glands
were homogenised in 350μL of 10% acetic acid using an
ultrasonic processor and centrifuged at 10,000×g for 1min.
The data were obtained by plotting the values on a linear
regression line generated from a standard adrenaline curve.
The left adrenal glands were used for experiments measuring
secretion (n = 10 for each group). The adrenal medulla
was dissected using a stereoscopic lens and ophthalmological
surgical instruments. To aid in manipulation, the isolated
medullae were impaled on steel needles and left to rest for
40 minutes in standard Krebs-HEPES solution.
2.5. Stimulation of Catecholamine Secretion. Costar 96-well
cell culture plates were used. Each well contained 200μL
of standard Krebs-HEPES or modiﬁed Krebs-HEPES solu-
tion containing 100μM carbachol, a synthetic analogue
of acetylcholine, 25mM caﬀeine, a well-known inducer
of calcium release from the endoplasmic reticulum, and
elevated (50mM) K+, which triggers plasma membrane
depolarisation. The pH of these solutions was maintained
between 7.0 and 7.2 at room temperature. The medullae
were incubated three times for 5 minutes each in a three-
well sequence in standard Krebs-HEPES solution and then
incubated for 5 minutes in modiﬁed Krebs-HEPES solution.
The medullae were then placed in 220μL of 10% acetic acid
and homogenised by sonication (at 60MHz for 10min) toExperimental Diabetes Research 3
extract nonsecreted catecholamines. Acetic acid (20μL) was
added to each well to preserve the secreted catecholamines.
Samples of secreted and remaining catecholamines were
assayed by the ﬂuorometric method described above.
2.6. Western Blot Analysis. Another batch of left adrenal
glands (n = 10 for each group) was processed for Western
blot analysis to quantify tyrosine hydroxylase (TH) and α-
PKC protein levels as previously reported [25], with some
modiﬁcations. Brieﬂy, the glands were homogenised in
0.3mL phosphate buﬀer (pH 7.4) containing 1μLp r o t e a s e
inhibitor cocktail (1mg/mL each of aprotinin, leupeptin,
and trypsin inhibitor) and centrifuged at 1120×gf o r
15min at 4◦C. Protein concentration in the supernatant was
determined by the Bradford method [26]. The proteins in
the supernatant were separated by SDS-PAGE using 20 and
100μg total protein for TH and α-PKC, respectively. The
proteins were electroblotted to a nitrocellulose membrane
(Hybond-P ECL membrane, Amersham Biosciences, UK),
and the membranes were incubated with Tris-buﬀered saline
(TBS) containing 5% (w/v) nonfat dry milk for 90min to
block nonspeciﬁc binding sites. The membranes were then
washed with TBS and incubated overnight at 4◦Ci np r i m a ry
antibody (monoclonalmouseanti-TH,Sigma-Aldrich, USA,
or mouse anti-α-PKC, Santa Cruz Biotechnology, USA)
diluted at 1:2000 in TBS containing 0.5% nonfat dry
milk. The membranes were then washed and incubated in
secondary HRP-conjugated goat antimouse antibody (Santa
Cruz Biotechnology, USA) diluted at 1:2000 in TBS con-
taining 0.5% nonfat dry milk for 1hr at room temperature.
Finally,theTHandα-PKCbandswerevisualisedbychemilu-
minescence (ECL Plus Kit, Amersham Biosciences, Sweden)
followed by exposure to autoradiographic ﬁlm (Hyperﬁlm
ECL, Amersham Biosciences). The area and intensity of the
bands were quantiﬁed using Abeletro software (UFJF-Juiz de
Fora,Brazil).Exceptwherestatedotherwise,allreagentswere
purchased from Sigma Chemical Co. (St. Louis, Mo, USA).
2.7. Plasma Adrenaline Measurement. Blood samples were
collected from 10 rats per group. After separating the plasma
(200–300μL per animal), it was stored under refrigeration
and transferred to microtubes containing sodium metabisul-
ﬁte antioxidant. High-performance liquid chromatography
(HPLC) was used to measure the adrenaline contained in
100μLs a m p l e s[ 27].
2.8. Glucose Tolerance Test. The intravenous glucose tol-
erance test (ivGTT) was performed after a 12-hour fast
(from 19:00 to 07:00h). The rats (n = 10 for each group)
underwent surgery to implant a cannula into the right
jugular vein. At 24 hours after surgery, a glucose load (1g/kg
bodyweight)wasdeliveredthroughoutthecannula.Animals
in a second group received an intraperitoneal injection of the
α-adrenergic agonist oxymetazoline (Oxy, 16nM/kg body
weight) 5min prior to the glucose load. Blood samples
(300μL) were collected from the same cannula before the
glucose load (t0) and 5 (t5), 15 (t15), 30 (t30), and 60 (t60)
min after the glucose injection; the t0 sample was used to
Table 1: Eﬀects of neonatal MSG treatment on adults rats.
Control MSG
Body weight (g) 278.60 ± 4.41 208.60 ± 3.31∗
Lee index 281.20 ± 1.07 300.70 ± 1.62∗
Epididymal fat pad
(g/100gbw) 1.58 ± 0.05 2.53 ± 0.06∗
Retroperitoneal fat pad
(g/100gbw) 1.34 ± 0.04 2.10 ± 0.04∗
Glycaemia (mg/dL) 101.80 ± 2.26 108.60 ± 6.99
Insulinaemia (ng/mL) 5.30 ± 0.72 15.06 ± 1.80∗
Adrenal glands (mg) 23.9 ± 0.39 12.06 ± 0.36∗
Adrenal glands
(mg/100gbw) 8.57 ± 0.12 5.79 ± 0.14∗
Data represent mean ± SEM. To all parameters, 20 rats were used for both
groups. student’s t-test was used. ∗P<0.05 compared to control.
measure plasma glucose and insulin concentrations by the
glucose-oxidase technique (Kit Bio Diagnostic Chemistry
Industry, Paran´ a-Brazil) and RIA, respectively, [28, 29].
2.9. Pancreatic Islet Isolation and Insulin Secretion. Rat pan-
creatic islets were isolated as previously described [30].
Batches of 4 islets (n = 20 batches of islets from 5 diﬀerent
rats) were preincubated for 60min in 1mL normal Krebs
solution containing (in mM): 120mM NaCl; 4.8mM KCl;
2.5mM CaCl2;1 . 2 m MM g C l 2;2 4m MN a H C O 3;5 . 6 m M
glucose. This solution was gassed with O2/CO2 (95/5%) to
maintain pH at 7.4 and supplemented with BSA (0.12%,
w/v) and used in the following steps. After equilibrating
to a low glucose concentration solution, the islets were
incubated for 60min in Krebs solution containing 5.6 or
8.3 or 16.7mM glucose. After preincubation, other islet
batches were incubated for 60min in the presence of the
α-adrenergic agonist. Adrenaline (1.0μM) was added to the
islets incubated in the Krebs solution with 16.7mM glucose
and 0.1μM of the adrenergic β-blocker propranolol, which
was used to avoid β-adrenoceptor potentiation eﬀects on
insulin secretion [31]. This concentration of adrenaline
(1.0μM) blocks glucose-induced insulin secretion [32].
Insulin concentrations were measured by RIA from aliquots
prepared from the incubations.
2.10.StatisticalAnalysis. Allresultsarepresentedasthemean
± SEM. Diﬀerences were considered statistically signiﬁcant
when P<0.05. One-way ANOVA with Bonferroni post
hoc test and Student’s t-test were performed using GraphPad
Prism version 5.00 for Windows (GraphPad Software, San
Diego, Calif, USA).
3. Results
As shown in Table 1, MSG treatment increased the epididy-
mal and retroperitoneal fat pad mass by 60.5 and 57.2%,
respectively, compared with control animals (P<0.001).
Indeed, the Lee index increased by 6.9% in obese rats4 Experimental Diabetes Research
MSG
Control
(
m
V
)
1s
1s
500
0
−500
(
m
V
)
500
0
−500
0
10
MSG
Control
2
4
6
8
Sympathetic activity
∗
S
p
i
k
e
s
/
5
s
Figure 1: Sympathetic activity in MSG-obese rats. The bars represent the frequency of nerve discharges in mean ± SEM (n = 8 animals
per group). Student’s t-test was used. ∗P<0.05 compared to control, by Student’s t-test. Representative records of nerve discharges from a
control and MSG-obese animal are shown.
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Figure 2: Adrenal medulla total catecholamine content, basal catecholamine secretion, and blood circulating adrenaline concentration in
MSG-obese rats. The bars represent mean ± SEM (n = 10–15 animals per group). ∗P<0.05 compared to control, by Student’s t-test.
compared with controls (P<0.05). These results conﬁrm
the eﬀectiveness of neonatal MSG treatment in inducing
adult obesity. Obese rats showed a nearly 3-fold increase
in insulinaemia compared with control rats (P<0.05);
in contrast, glycaemia was unchanged in both groups.
Moreover, adrenal gland mass was reduced 49.5% in pre-
diabetic obese rats compared with control rats (P<0.001).
Recordings of sympathetic nerve activity are shown in
Figure 1. In both resting, and fasting states, the sympathetic
ﬁring rate was 58.8% lower in pre-diabetic obese rats
compared with control rats (P<0.05).
Figure 2 shows total catecholamine stores in the adrenal
glands, basal catecholamine secretion from isolated adrenal
medullae and fasting plasma adrenaline levels. Total adrenal
catecholamine content was increased by 40.3% in pre-
diabetic obese rats compared with controls (P<0.01).
However, the pre-diabetic rats showed a 60% reduction in
basal catecholamine secretion from the adrenal medulla and
32% lower plasma adrenaline concentration compared with
the control animals (P<0.05).
Figure 3 shows that carbachol, caﬀeine, and potassium
each induced higher levels of catecholamine release in obese
rats compared with control rats. Speciﬁcally, carbachol,
caﬀeine, and potassium led to a 1.7-, 2.4-, and 2.5-fold
increase in catecholamine secretion, respectively, from pre-
diabetic obese adrenal medullae relative to controls.Experimental Diabetes Research 5
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Figure 3: Adrenal catecholamine secretion in MSG-obese rats. The bars represent mean ± SEM (n = 8–10 animals per group). ∗P<0.05
compared to control, by Student’s t-test.
As shown in Figure 4, TH protein levels decreased 37.6%
inpre-diabetic ratscomparedwithcontrolrats(P<0.05).In
contrast, α-PKC protein levels did not diﬀer between the two
groups.
Figure 5 shows that isolated islets from both groups
responded in a dose-dependent manner when stimulated
by glucose; however, the dose-response curve was much
steeper in islets from pre-diabetic obese animals than in
lean animals. In low (5.6mM) glucose, insulin secretion
was similar between obese and control islets. On the
other hand, pre-diabetic obese islets secreted 127 and
56% more insulin in high-glucose solutions of 8.3 and
16.7mM, respectively, compared with control pancreatic
islets (P<0.05). Adrenaline inhibited glucose-stimulated
insulin secretion in islets from both groups; however, this
inhibition was more pronounced in islets obtained from
pre-diabetic obese rats. The insulin secretion stimulated by
16.7mM glucose was inhibited by 72 and 47% in pancreatic
islets isolated from pre-diabetic obese and control animals,
respectively, (P<0.05).
Figure 6 shows the results of the ivGTT test. Following
a glucose load of 1g/kg body weight, glycaemia increased in
both groups; however, in pre-diabetic obese rats, the plasma
glucose concentration was 78% higher than the control
group(P<0.05)at5min.Thefastingglycaemiawasrestored
at 30min and was maintained until the latest time point
measured (60 min) for both groups. The glucose intolerance
in pre-diabetic obese rats can be clearly appreciated by con-
sidering the area under the curve (AUC) of glycaemia during
ivGTT (Figure 6), which shows that obese animals had 65%
higher glycaemia than control rats (P<0.05). Moreover,
oxymetazoline induced 30 and 93% more AUC glycaemia in
pre-diabetic obese and control rats, respectively, (P<0.05).
Blood insulin levels during ivGTT are also presented in
Figure 6 and show that plasma insulin levels increased in
parallel with the rise in glucose levels in both groups; more-
over, as with glucose levels, plasma insulin levels increased
to a greater magnitude in obese rats. Plasma insulin levels
were 280, 76, and 190% greater in pre-diabetic obese rats at
5, 15, and 60 min, respectively, relative to control rats (P<
0.05). Insulin AUC was 320% higher in obese rats compared
with control rats (P<0.05). The oxymetazoline eﬀect
on insulinaemia is also presented as AUC data in Figure 6.
Oxymetazoline inhibited insulinlevelsby76and35%inpre-
diabetic obese and control animals, respectively, (P<0.05).
4. Discussion
Energy homeostasis is regulated by the neural brain network,
principally in the hypothalamus [6, 7]. In rodents, lesions
in the ARC during the neonatal period lead to obesity
in adulthood [33]. A frequently used model of obesity is
neonataladministrationofMSG;thistreatmentkillsneurons
in the ARC [33, 34]. These pre-diabetic obese rats have
massive adipose tissue accumulation, delayed development,
and elevated insulin levels [35–37], all of which were also
found in the present study. Low levels of growth hormones
are found in obese animals and are responsible for their
reducedsizeandmusclemass.Insuﬃcientcirculatinggrowth
hormone levels also contributed to the reduced lipolytic
capacity that obese animals exhibit [35, 38].
Reduced SNS activity plays an important role in several
rodent models of obesity [15]. Genetic models of obesity
exhibit decreased SNS activity to brown adipose tissue (BAT)
and other peripheral organs [15, 39]. Levin demonstrated a
reduced turnover of noradrenaline in organs, including the
brain, of obesity-prone rats that preceded any increase in
body weight [40]. SNS dysfunction has also been observed in
obese humans. Saad et al. showed that sympathetic activity
is an indicator of energy expenditure in Caucasians [41].6 Experimental Diabetes Research
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On the other hand, some authors have reported high SNS
activation to the heart, blood vessels, and kidneys, which
might be critical in the development of obesity-related
hypertension [42]. Indeed, Davy and Orr reviewed SNS
activity in human obesity and discussed the possibility of
SNS outﬂow being diﬀerentiated according to its target
organ, suggesting tissue speciﬁcity [10]. Direct evidence of
weak SNS activity was demonstrated in the present study by
recording the sympathetic ﬁring rate in the superior cervical
ganglion of pre-diabetic obese rats. However, data obtained
from exercised, food-deprived, or fasted animals, as well as
animals treated with a sympathoexcitatory agent, showed
that when suﬃciently stimulated, the SNS of MSG-obese
rodents can activate suﬃciently to drive physiological
responses that are comparable to lean animals [21, 43–45].
Failed sympathoadrenal function has been described as
animportantfeatureintheonsetofobesity[46–48].Accord-
ing to Jocken and Blaak, impaired catecholamine-induced
lipolysis can contribute to the adipose tissue development
[49]. Data obtained in our laboratory have demonstrated
that MSG-obese mice have decreased basal catecholamine
secretion from the adrenal medulla compared to nor-
mal mice [50]. Indeed, MSG-obese mice have diminished
adrenaline excretion and noradrenaline turnover in BAT8 Experimental Diabetes Research
compared to control mice [51, 52]. Nicotine signiﬁcantly
increases noradrenaline turnover, BAT oxygen consumption,
and resting metabolic rate and signiﬁcantly reduces body
weight in MSG-obese mice without aﬀecting food intake
[43]. In support of a general reduction in SNS activity
in obesity, we found decreased plasma circulating levels of
adrenaline in pre-diabetic obese rats. Some authors have
concludedthattheseresultsindicatelowsympatheticactivity
that leads, at least in part, to decreased energy expenditure
and fat mobilisation [51, 52].
Our results also show that obese rats have an increased
catecholamine secretion response to all of the secretagogues
that were tested in the adrenal medulla incubations. We
believe that excitation-secretion coupling in adrenal chro-
maﬃn cells of pre-diabetic obese rats is physiologically pre-
served, as catecholamine secretion could still be induced by
membranedepolarisation(triggeredbyelevatedextracellular
potassium), activation of cholinergic receptors (by carba-
chol),andcalciumreleasefromintracellularstores(triggered
by caﬀeine). The relatively high total catecholamine content
that we measured in obese rats may be the result of low
SNS activity, which contributes to reduced catecholamine
secretion.
TH catalyses the rate-limiting step in the biosynthe-
sis of the catecholamines dopamine, noradrenaline, and
adrenaline [53]. We previously reported that adult obese
mice have decreased expression of the enzymes TH and
dopamine beta-hydroxylase [25]. Similar TH results were
observed in obese rats. The results of our current study
also show that, despite this decrease in TH expression,
catecholamine content is increased in the adrenal gland of
prediabetic obese rats, which can be the result of decreased
pre-synaptic stimulation of adrenal medulla chromaﬃn
cells. Dysfunction of the SNS eﬀerent signal produces low
blood adrenaline levels, as observed in MSG-obese rats.
Furthermore, TH expression may be considered a marker
of cholinergic activity, as stimulation of acetylcholine recep-
tors induces both TH enzyme activation and TH protein
expression [54]. Acetylcholine released from the splanchnic
nerve interacts with cholinergic receptors in the adrenal
medulla, leading to activation of several protein kinases,
including protein kinase C (PKC) [55], which catalyses TH
phosphorylation and TH gene transcription [53].
No signiﬁcant diﬀerence in α-PKC expression was
observed in adrenal chromaﬃn cells of MSG-obese rats
compared to controls; however, additional studies of PKC
activity are needed to conﬁrm this ﬁnding, as this kinase
is activated primarily via the muscarinic signalling pathway.
Indeed, Akaike et al. showed that PKC activation results
in potassium channel phosphorylation, which reduces the
channel’s conductance and consequently induces membrane
depolarisation, the latter of which contributes to increased
catecholamine secretion [56].
Disruption of glycaemia homeostasis is a hallmark of
obesity and is primarily attributed to insulin resistance [57–
59]. We found that MSG-obese rats are glucose intolerant,
conﬁrming previously published results [36, 60, 61]. The
elevated insulin levels found in MSG-obese rats can reﬂect
insulin resistance. Molecular studies have demonstrated that
MSG-obese animals have a decrease in signalling of their
insulin-stimulated IRS/PI3K/Akt pathway in muscle and
adipose tissue, which may be an important hallmark of
insulin resistance of those animals [62]. Indeed, insulin
binding to membrane receptors in liver, skeletal muscle, and
adipocytes is decreased in MSG-obese rats [61].
The high insulin levels in pre-diabetic obese rats play
a central role in fat cell proliferation and insulin resistance
[62]. White adipose tissue in MSG-obese rats has elevated
lipogenesis capacity and compensatory responsiveness to
insulin by the Cbl and IRS2 pathways, which may mediate
the insulin antilipolytic eﬀect [62]. When MSG-obese rats
undergo early vagotomy (at 30 days of life), hyperinsuli-
naemia is blocked, and fat accumulation is dramatically
reduced [63]. Indeed, surgery to remove fat in 15-week-
old MSG-obese rats improved their lipid proﬁle and insulin
resistance [64].
Furthermore, these results show that hyperinsulinaemia
in obese rats is sustained by increased glucose responsiveness
in isolated pancreatic islets. Increased responsiveness to
glucose by pancreatic islets is also a feature of other obesity
models and may be an adaptation to altered ANS tonus
to endocrine pancreas with high parasympathetic activity
[65, 66]. Early vagotomy prevents high-glucose-stimulated
insulin secretion in MSG-obese rats [36]. Indeed, pancreatic
isletsfromZucker(fa/fa)rats,ageneticanimalmodelofobe-
sity,alsohaveahighresponsetoglucose,andisletsfromthese
animals have high levels of glucose utilisation and oxidation,
which contribute to their observed hyperinsulinaemia [67].
Alpha-adrenergic activation has an inhibitory eﬀect on
glucose-stimulated insulin secretion, and this is accentuated
in islets obtained from pre-diabetic obese rats, indicating
that SNS tonus to islets may be reduced in obese rats. Islets
isolated from both ob/ob mice and Zucker (fa/fa) rats, two
genetic models of obesity, have higher responsiveness to
the inhibitory action of noradrenaline [68, 69]. Cruciani-
Guglielmacci et al. investigated an animal model of obesity
obtained by a high-fat diet and reported that these animals
developed severe glucose intolerance and insulin resistance
that were due to increased glucose-induced insulin secretion.
The authors further showed that injections of the α2-
adrenergic receptor agonist oxymetazoline (even at low
concentrations) reduced glucose-induced insulin secretion
intheobesegroup;thiseﬀectwasnotobservedinthecontrol
group. Low SNS activity in rats that received a high-fat
diet may be responsible for their islet hypersensitivity to
oxymetazoline, as concluded by the authors [70]. Our results
also showed that oxymetazoline causes a profound decrease
in blood insulin concentration in pre-diabetic obese rats,
which suggests that insulin secretion is potently inhibited.
5. Conclusions
Our data support the hypothesis that MSG-obesity onset is
dependent on reduced sympathetic tonus, including sym-
pathoadrenal axis activity; however, physiologically, adrenal
medulla function is preserved in these rats. Our data show
that the low SNS activity observed in pre-diabetic obese
rats leads to reduced basal catecholamine secretion from theExperimental Diabetes Research 9
adrenal medulla, which reﬂects a decreased concentration
of plasma adrenaline. Indeed, the latter may contribute to
the pancreatic islet’s high sensitivity to adrenaline, indicating
that the inhibitory eﬀect of catecholamines on insulin
secretion may be impaired in pre-diabetic obese rats. In
addition to helping understand the mechanisms underlying
obesity, this study may be helpful in developing strategies for
treating and preventing the onset of obesity and diabetes by
targeting sympathoadrenal axis activation.
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